by Stacey Hawkins | Apr 21, 2020 | Oncology
Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of treatment, while inroads against... 
by Stacey Hawkins | Feb 26, 2019 | Oncology
PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult... 
by Stacey Hawkins | Oct 15, 2015 | Drug Discovery
Drug Discovery Via Natural Products Half of the 2015 Nobel Prize in Medicine went to Satoshi Omura and William C. Campbell for their work leading to the discovery of the drug avermectin, used in the treatment of parasitic diseases. The other half went to Youyou Tu for... by Stacey Hawkins | Jan 8, 2015 | Regulation
The FDA ushered in six new drugs just before the close of 2014, bringing the final tally to 41– the highest rate since 1996, when the agency approved 53 drugs. 2014 drug approvals were notable not only for their quantity, but also their quality. A number of new drugs...
